

DAFTAR PUSTAKA

- Abdou, H., Hanna, S., Muhammad, N., 2000. Dissolution, In: Alfonso R Gennaro (Ed.), **Remington: The Science and Practice of Pharmacy**, 20th ed., Philadelphia: Lippincott Williams & Wilkins. p. 672-687.
- Aitipamula, S., Chow, PS., Tan, RBH. 2009. Dimorphs of a 1:1 cocrystal of ethenzamide and saccharin : solid-state grinding methods result in metastable polymorph. *Cryst Eng Comm.* 11: p. 889-895.
- Alhalaweh, A. 2012. Pharmaceutical Cocrystal (Formation Mechanisms, Solubility Behaviour and Solid-State Properties). *Thesis.*, Lulea University of Technology. ISSN: 1402-1544. p. 15-36.
- Almarsson, O., Zaworotko, MJ. 2004. Crystal engineering of the composition of pharmaceutical phases. Do pharmaceutical co-crystals represent a new path to improved medicines. *Chem Commun* : p. 1889-1896.
- Ansel, H.C., Popovich, N.G., Allen, L.V., 2011. **Pharmaceutical Dosage Form and Drug Delivery System**, 9th ed. Malvern : Williams & Wilkins. p.104.
- Al-Taani, B., Salem, M.S., Al Taani, S. 2009. Influence of Polyvinyl Pyrrolidone Addition during Crystallization on the Physicochemical Properties of Mefenamic Acid Crystals. *JJPharmScie.* Vol.2 p. 86-98.

- Basavoju, S., Bostrom, D., Velaga, S.P., 2006. Pharmaceutical Cocrystal and Salts of Norfloxacin. *Cryst. Growth* Vol 6: p. 2699-2708.
- Basavoju, S., Bostrom, D., Velaga, S.P., 2007. Indomethacin-Saccharin Cocrystal:Design, Synthesis and Preliminary Pharmaceutical Characterization. *Pharm. Res.*, Vol 25 No 3. p. 530-41.
- Bis, J. A., Zaworotko, M. J., Vishweshwar, P., McMahon, J.A. 2005., Pharmaceutical co-crystals. *Cryst. Growth & Des*, 5, p. 1169.
- Brunton, L.L., Lazo, J.S., Parker, K.L. 2006. Goodman & Gilman's the Pharmacological Basis of Therapeutics 11th Ed. *The McGraw-Hill Companies*. Inc. chapter. 26.
- Budavari., Susan., Maryadele, J.O'Neil., Ann Smith., Patricia E.Heckelman., Joanne, F.Kinneary. 2001. *The Merck Index*, New Jersey : Merck Research Laboratories Division Of Merck &CO., Inc, p. 473-474.
- Chandramouli, Y., Gandhimathi, R, Yasmeen, B. R., Vikram, A., Mahitha, B dan Imroz, S.M. 2012. Review On Cocrystal As An Approach With Newer Implications in Pharmaceutical Field. *IJMCA* 2(2) p. 91-100.
- Chaudhary, A., Nagaich, U., Gulati, N., Sharma, V.K., Khosa, R.L., 2012. Enhancement of solubilization and bioavailability of poorly soluble drugs by physical and chemical modifications : A recent review., *JAPTR*., p. 32-67.

Cheney, Miranda L., Shan Ning, Healey, E.R., Hanna, M., Wojtas, L., Zaworotko, M.J., Sava, V., Song, S., Sanchez-Ramoz, J.R. 2009. Effect of Crystal Form in Solubility and Pharmacokinetics: A Crystal Engineering Case Study of Lamotrigine. *Cryst. Growth & Des.*, 2010, Vol 10, p. 394-405.

Departemen Kesehatan Republik Indonesia., 1995. *Farmakope Indonesia*. Edisi ke 4. Jakarta : Departemen Kesehatan Republik Indonesia p. 43, p. 748.

Durgashanskar, P., Ashish, P., Anjali, P. 2012. A Review on Co-Crystal., *JSRP*. p.

Erizal Zaini, et al. 2010. Cocrystalline phase transformation of binary mixture of trimethoprim and sulfamethoxazole by slurry technique. *AJPCR*. 3(4). p 26-29..

Fabian, L., Hamill, N., Eccles, K.S., Moynihan, H.A., Maguire, A.R., McCausland, L., Lawrence, S.E. 2011. Cocrystals of Fenamic Acids with Nicotinamide. *Cryst. Growth & Des.* 11 (8):3522-3528 p. 1-24.

Food and Drug Administration., 2000. Waiver of In Vivo Bioavailability and Bioequivalence Studies for Immediate-Release Solid Oral Dosage Forms Based on a Biopharmaceutics Classification System : *U.S Departement of health and Human Service*. p. 1-13.

Fotaki, N., Tomaszewska, I., Karki, S., Shur, J., Price, R. 2013. Pharmaceutical characterization and evaluation of cocrystals: Importance of in vitro dissolution conditions and type of conformer. *IJPharm*. p.380-388.

- Gao, Y., Gao, J., Liu, Z., Kan, H., Zu, H., Sun, W., Zhang, J., Qian,S. 2012., Coformer selection based on degradation pathway of drugs : a case study of adefovir dipivoxil-saccharin and adefovir dipivoxil-nicotinamid cocrystals., *Int J Pharm.* 15;438 (1-2): p. 327-35.
- Goldberg, A.H., Gibaldi, Kanig, J.L. 1996. Increasing dissolution rates and gastrointestinal absorption of drug via soil solution and eutectic mixture, experimental evolution of eutectic mixture; urea acetaminophen system. *J.Pharm Sci.* 55: p. 482-487.
- Horst, J.; Cain, P., Deij, M.A. 2009. Discovering new co-crystals .*Cryst. Growth* Vol. 9: p. 1531-1537.
- Jackson, J.V., Moss, M.S., Widdop, B., Moffiat, A.C. 1986. *Clarke's Isolation & Identification of Drugs*, 2nded, Pharmaceutical Press, p.727.
- Jasud, S., Warad, S., Rahul, S., Jagdale, G., Zinjad, S. 2013., Cocrystal: A Novel Approach for Bioavailability Enhancement., *WJPPS*. Vol.2 Issue 6, p. 4682-4697.
- Jatwani, S., Rana, A.C., Singh, G., Aggarwal, G. 2011. An Overview on Solubility Enhancement Techniques For Poorly Soluble Drugs and Solid Dispersion As an Eminent Strategic Approach. *IJPSPR*. Vol.3 Issue 4. p. 942-956.
- Jayasankar, A., Somwangthanaroj, A., Shao, ZJ., Rodriguez-Hornedo, N. 2006. Co-crystal formation during cogrinding and storage is mediated by amorphous phase. *Pharm Res.* 23: p. 2381-2392.

- Jayasankar, A., Good, DJ., Rodrigues-Hornedo, N. 2007. Mechanism by which moisture generates cocrystal. *Mol Pharm.* 4: p. 360-372
- Jung, J., Perrut, M. 2001. Particle design using supercritical fluids: Literature and patent survey. *Journal Supercritical Fluids*, 20, p. 179-219.
- Keshavarao, K.P., Mudit, D., Selvam, P. 2011. Improvement of Solubility And Dissolution Rate of Mefenamic Acid By Solid Dispersions in PEG 4000., *IRJP.*, p. 207-210.
- Keshavarao, K.P., Mudit, D., Bhardwaj, Y., Selvam, P. 2011. Enhancing Solubility and Dissolution of Mefenamic Acid by Freeze Drying Using β -Cyclodextrin., *IRJP.* p. 146-150.
- Khan, K.A., 1975. The Concept of Dissolution Efficiency. *J. Pharm. Phamac.*, 27(1). p. 48-9.
- Kothur, R.R., Swetha, A.S., Bondili, N.P. 2012. An Outline of Crystal Engineering of Pharmaceutical Co-Crystals and Applications : A Review. *IJPRD* vol 4 (08): p. 84-92.
- Mc Evoy, G.K.(Ed.). 2002. *AHFS Drug Information*, book 4, USA : American Society of Health System Pharmacists, p. 2005-2008.
- Mcnamara, D.P., S.L Childs, J. Giordano, A larricchio, J.Cassidy, M.S Shet, R.Mannion, E. O'Donnel, and A.Park., 2006. Use of a glutaric acid cocrystal to improve oral bioavailability of a low solubility API. *Pharm res.* 23: p. 1888-1897.

Mirza, S., Miroshnyk, I., Heinamaki, J., Yliruusi, J., 2008. Co-crystal: an Emerging Approach for Enhancing Properties of Pharmaceutical Solids. *Dosis Vol 24* No.2: p. 90-95.

Mohanachandran, P.S., Sindhumol, P.G., Kiran, T.S., 2010. Enhancement of Solubility and Dissolution Rate : An Overview., *Pharmacie Globale (IJCP)*., p. 1-10.

Mudit, D., Ashwini, G.K., Parthasarthy, K.K. 2012. Enhancing The Dissolution Of Polymorphs I and Polymorphs II of Mefenamic Acid By Spray Drying., *Turk J.Pharm Sci.* 9(1). p. 13-26.

Mundhe, A.V., Kumar, F.N., Radheshyam, B.K. 2013. Cocrystallization : An Alternative Approach For Solid Modification. *JDDT*. 3(4). p. 166-172.

Nagabhushanam, MV., Sudha Rani, A. 2010. Dissolution Enhancement of Mefenamic Acid Using Solid Dispersions In Crospovidone., *IJPPS*. p. 16-19.

Nagabhushanam, MV., Rao Prasada, V., Prabhakar CH. 2011. Formulation and Evaluation of HP- β -Cyclodextrin Complexes of Mefenamic Acid Tablets., *IJPT*. p. 2669-2679.

Nehm S.J., Rodríguez-Spong B., Rodríguez-Hornedo N. 2006. Phase solubility diagrams of co-crystals are explained by solubility product and solution complexation. *Cryst Growth* Vol.6: p. 592-600.

- Padrela, L., Rodrigues, MA., Velaga, SP., Matos, HA., de Azevedo, EG. 2009. Formation of indomethacin-saccharin cocrystals using supercritical fluid technology. *Eur J Pharm Sci* 38 : p. 9-17.
- Patil, B.P., Udupi, RH., Gupta, VRM., Prasad, B S G. 2010. Development of dissolution medium for poorly water soluble drug mefenamic acid. *RJPBCS* 1 (4). p. 544-549.
- Qiao, N., Li, M H., Schlindwein, W., Malek, N., Davies, A., Trappitt, G. 2011. Pharmaceutical cocrystals : An overview. *Int. J. Pharm.* 419 : p. 1-11.
- Rahman, Z., Agarabi, C., Zidan, Ahmed S., Khan, S.R dan Khan, Mansoor A. 2011. Physico-mechanical and stability Evaluation of Carbamazepine Cocrystal with Nicotinamide. *AAPS PharmSciTech*, 12(2), p. 693-704.
- Rahman, Z., Samy, R., Saveed, V.A., Khan, M.A. 2012., Physicochemical and mechanical properties of carbamazepine cocrystals with saccharin., *Pharm Dev Technol.*, 17(4): p. 457-65.
- Rao, P., Nagabhushanam, M.V. 2011. Enhancement Of Dissolution Profile of Mefenamic Acid By Solid Dispersion Technique., *IJRPC*. p. 1127-1134.
- Rao, P.CH., Nagabhushanama, MV., Prabhakar, CH. 2011. Enhancement of Dissolution Rate of Poorly Soluble Drug Mefenamic Acid by Solid Dispersion., *RJPBCS*. p. 1025-1035.
- Rohrs, B.R., 2001. Dissolution Method Development for Poorly Soluble Compound. *Dissolution Technologies*. 8(3), p.1-5.

Rowe, C.R., Sheskey, J.P., and Weller, P.J. 2003. *Handbook of Pharmaceutical Excipients*, Ed. 4th, London : Pharmaceutical Press, p. 529-534.

Sambaasiva Rao, K.R.S., Nagabhushanam, MV., Chowdary, K.P.R. 2011 *In vitro* dissolution studies on solid dispersions of mefenamic acid., *Pharm res.*, Vol 73, p. 243-247.

Sayjani, J.K., Pathak, C.D., Sayjani, K.T., Gajjar, A.K. 2013. Cocrystal Formation Of Paracetamol With Indomethacin And Mefenamic Acid An Efficient Approach To Enhance Solubility. *IJPPS*. Vol.5, Issue 4. p. 414-419.

Schultheiss N, Newman A. 2009. Pharmaceutical co-crystals and their physicochemical properties. *Cryst Growth*. Vol.9 : p. 2950–2967.

Sekhon, B. S. 2012. Drug-drug co-crystals. DARU **J. Pharm Sci** , 20: p. 45

Sekhon, B. S. 2012. Nutraceutical Cocrystals: An overview. **RGUHS J Pharm Sci**, 2(2). p. 16-25.

Setyawan, D., Sari, R., Yusuf, H., Primaharinastiti, R. 2013., Preparation and Characterizationof Artesunate – Nicotinamide Cocrystal by Solvent Evaporation and Slurry Method., *Asian J Pharm.Clin Res.* Vol.7. p. 62-65.

Shariff, JS., Saleem, S., Kumar, ANP., Kumar, BA., Madhusudhan, P. 2013. Formulation And Evaluation of Mefenamic Acid Solid Dispersions Using PEG 4000., *IRJP*. p. 155-159.

- Shiraki, K., Takata, N., Takano, R., Hayashi, Y., Terada, K. 2008. Dissolution improvement and the mechanism of the improvement from cocrystallization of poorly water-soluble compounds. *Pharm Res.* 25 : p. 2581-2592.
- Sinko, P. 2006. *Physical Pharmacy*. 5th ed. Baltimore : Lippincott Williams & Wilkins. p. 300-317.
- Siregar, C.J.P. dan Wikarsa, S. 2002. *Teknologi Farmasi Sediaan Tablet Dasar–Dasar Praktis*. Jakarta : EGC p. 54.
- Siswandono & Soekardjo, Bambang. 2000. *Prinsip-Prinsip Rancangan Obat*, Cetakan kedua. Surabaya : Airlangga University Press. p. 300.
- Stahly GP. 2009. A survey of co crystals reported prior to. *Cryst. Growth & Des*, 9, 2009, p. 4212–4229.
- Stanton, M.K., Tufekcic, S., Morgan C., Bak, A., 2009. *Cryst. Growth Des.*, 9, p. 1344-1352.
- Sweetman, S.C. 2009. *Martindale : The Complete Drug Reference*. Thirty-sixth edition. London : Pharmaceutical Press. p. 80.
- Takata, N., Takano, R., Uekusa, H., Hayashi, Y., Terada, K. 2010. A spironolactone-saccharin 1:1 cocrystal hemihydrate. *Cryst. Growth.* 10 : p. 2116-2122.
- Thakuria, R., Delori, A., Jones, W., Lipert, M.P., Roy, L., Hornedo, NR. 2013. Pharmaceutical cocrystals and poorly soluble drugs. *IJPharm.* 453: p. 101– 125.

- Tiekink, E.R.T. dan Vittal, J.J. 2006. Crystal Engineering of Pharmaceutical Cocrystals. In: Vishweshwar, P., McMahon, J.A., dan Zaworotko, M.J. *Frontiers In Crystal Engineering*. West Sussex : John Wiley & Sons Ltd., p. 25-45.
- United State Pharmacopoeial Convention, 2007. *USP 30 NF 25*, Rockville. MD The United States Pharmacopoeial Convention, Inc. p. 1202, p. 2560.
- Velaga, SP., Basavouju, S Bostrom D. 2008. Norfloxacin saccharinate-saccharin dihydrate cocrystal – A new pharmaceutical cocrystal with an organic counter ion. *J Mol Struct.* 889: p. 150-153.
- Vishweshwar, P., Nangia, A., Lynch, VM. 2003. Molecular complexes of homologous alkanedicarboxylic acids with isonicotinamide: X-ray crystal structures, hydrogen bond synthons, and melting point alternation. *Cryst. Growth Des.* 7 : p. 1007-1026.
- Vishweshwar, P., McMahon, JA., Bis, JA., Zaworotko, MJ. 2006. Pharmaceutical co-crystals., *J Pharm Sci*, 95, p. 499-516.
- Walsh, RDB., Bradner, MW., Fleischman S., Morales, LA., Moulton, B, Rodriguez-Hornedo, N., Zaworotko, MJ., 2003 Crystal engineering of the composition of pharmaceutical phases. *Chem Commun.* p. 186-187.

Williams, H.D., Trevaskis, N.L., Charman, S.A., Shanker, R.M., Charman, W.N., Poulon, C.W., Porter, C.J.H., 2013. Strategies to Address Low Drug Solubility in Discovery and Development, *Pharmacological Reviews*, Vol 65, No.2. p. 315-499.

Yu Lx., Amidon, GL., Polli, JE., Zhao, H., Mehta, MU., Conner, DP., Shah, VP., Lesko, LJ., Chen, ML., Lee, VH., Hussain, AS. 2002. A Bio pharmaceutics classification system: the scientific basis for Biowaiver Extension. *Pharm. Res.*, Vol 19: p. 921-925.

Zhang, J., Qian, S., Gao, Y., Gao, J., Liu, Z., Kan, H., Zu, H., Sun, W. 2012. Coformer selection based on degradation pathway of drugs: A case study of adefovir dipivoxil-saccharin and adefovir dipivoxil-nicotinamide cocrystals. *IJPharm.* p. 327-335.